Loading
A phase 3 trial testing TGRX-326 in non-small-cell lung cancer, active and no longer recruiting.
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06082635, led by Shenzhen TargetRx with Sun Yat-Sen University Cancer Center, and active but no longer recruiting on the registry. Official title: A Multi-centered, Randomised, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 321 participants (actual). The study started in 2023-12-14 and primary completion is expected in 2026-04-30. No results have been posted on ClinicalTrials.gov.
Shares TGRX-326, Shenzhen TargetRx, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer.